Everyday Health on MSN

Obstructive vs. Nonobstructive Hypertrophic Cardiomyopathy (HCM): What Your Diagnosis Means for Treatment and Lifestyle

Learn the key differences between obstructive and nonobstructive HCM, including how your specific diagnosis can impact ...

FDA approves Myqorzo for symptomatic obstructive hypertrophic cardiomyopathy

The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...

CareMed Has Been Selected as a National Specialty Pharmacy Provider for MYQORZO(TM) (aficamten)

NEW HYDE PARK, N.Y., Jan. 12, 2026 (GLOBE NEWSWIRE) -- CareMed (R) , an independent specialty pharmacy, has been selected as a pharmacy partner by Cytokinetics for MYQORZO (TM) (aficamten), indicated ...
Business Insider

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...
MPR

Mavacamten Significantly Improves Symptomatic oHCM in Adolescent Population

Mavacamten is a selective, reversible, allosteric cardiac myosin inhibitor. It is approved under the brand name Camzyos ® for the treatment of adults with symptomatic New York Heart Association class ...
Healio

Optimizing mavacamten for treatment of obstructive hypertrophic cardiomyopathy

Please provide your email address to receive an email when new articles are posted on . Mavacamten presents dosing and drug-drug interaction challenges. A multidisciplinary approach featuring a ...
The American Journal of Managed Care

Real-World Risks of Mavacamten Use for Obstructive Hypertrophic Cardiomyopathy

Mavacamten treatment in oHCM patients led to new atrial fibrillation/flutter and heart failure, with frequent acute care episodes within months. Nearly half of the patients required dose adjustments, ...
Monthly Prescribing Reference

Aficamten Looks Promising for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Treatment with aficamten improved exercise capacity in patients with symptomatic obstructive hypertrophic cardiomyopathy when compared with placebo. Treatment with aficamten improved exercise capacity ...
Healio

‘One giant leap for HCM’: Gene therapy may reverse hypertrophic cardiomyopathy

Please provide your email address to receive an email when new articles are posted on . A first-in-human phase 1 trial is testing a novel gene therapy for hypertrophic cardiomyopathy. The one-time ...
Mena FN

Cytokinetics Announces FDA Approval Of MYQORZOTM (Aficamten) For The Treatment Of Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy To Improve Functional Capacity ...

Company to Host Investor Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the ...
JSTOR Daily

Hypertrophic cardiomyopathy β-cardiac myosin mutation (P710R) leads to hypercontractility by disrupting super relaxed state

Hypertrophic cardiomyopathy (HCM) is the most common inherited form of heart disease, associated with over 1,000 mutations, many in β-cardiac myosin (MYH7). Molecular studies of myosin with different ...